Business Wire

Leman Micro Devices: World-first Clinical Trial Proves Cuffless Mobile Device Sensor and App Measures Blood Pressure With Same Accuracy as Cuff-based Machines

6.1.2022 22:16:00 EET | Business Wire | Press release

Share

Leman Micro Devices’ e-Checkup system has successfully completed a world-first clinical trial and proven it is the only completely cuffless and calibration-free sensor and app capable of measuring blood pressure with the accuracy demanded for medical use.

Hypertension (high blood pressure) kills over 10 million people per year. Many people do not know they have it because diagnosis and monitoring require an expensive and cumbersome automatic cuff or repeated checks by a doctor. e-Checkup and its small V-Sensor, which costs only a few dollars, have been developed and industrialised by LMD to be built into a mobile phone or into a wearable or a pocket monitor connected to a phone by Bluetooth and the app on the phone analyses the measurements from the sensor to deliver a clinically-accurate personal blood pressure measurement in under 60 seconds.

The clinical trial was conducted by SVS Medical College in Mahabubnagar, India, a country with a high incidence of hypertension and a large rural population with limited access to a doctor. The trial adhered to the internationally recognised ISO 81060-2 standard that sets the requirements for automatic blood pressure monitors used by hospitals, doctors and consumers. It found that e-Checkup fully complied with all the criteria of the standard.

Dr K. Saumya, Principal Investigator for the trial, said “This device will be a real life-saver in India. It is small and affordable and will alert people to the need to consult a doctor about their blood pressure before they have symptoms and before it gives rise to awful consequences such as stroke, kidney damage, heart attack or blindness”.

Mark-Eric Jones, CEO of LMD added: “We would like to thank SVS for its careful and professional conduct of this trial which will underpin our work to bring this accessible and affordable medical device to global markets. This landmark trial proves that our patented, unique technology makes accurate, life-saving measurements. No other portable device in the world can measure blood pressure without a cuff, either to make the measurement or to calibrate the device frequently.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Leman Micro Devices
Mark-Eric Jones
CEO
mej@leman-micro.com
www.leman-micro.com

BWW Communications
Anna Johnston
Senior Account Director
anna.johnston@bwwcomms.com
+44-1491-636393
+44-7493-866478
www.bwwcomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i

Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release

Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye